Valuation: Geron Corporation

Market Cap 720M 643M 594M 538M 1.01B 68.31B 1.02B 7.14B 2.83B 35.79B 2.7B 2.64B 113B P/E 2026 *
-25.5x
P/E 2027 * 16.5x
Enterprise Value 720M 643M 594M 538M 1.01B 68.31B 1.02B 7.14B 2.83B 35.79B 2.7B 2.64B 113B EV / Sales 2026 *
3.06x
EV / Sales 2027 * 2.11x
Free-Float
99.92%
Yield 2026 *
-
Yield 2027 * -
1 day-0.88%
1 week-4.27%
Current month-8.94%
1 month-11.11%
3 months-21.13%
6 months-25.33%
Current year-15.15%
1 week 1.08
Extreme 1.08
1.24
1 month 1.08
Extreme 1.08
1.27
Current year 1.08
Extreme 1.08
2.01
1 year 1.04
Extreme 1.04
2.01
3 years 1.04
Extreme 1.04
5.34
5 years 0.99
Extreme 0.9899
5.34
10 years 0.75
Extreme 0.75
6.99
Manager TitleAgeSince
Chief Executive Officer 54 2025-08-06
Director of Finance/CFO 59 2023-09-24
Chief Tech/Sci/R&D Officer - 2025-09-30
Director TitleAgeSince
Director/Board Member 76 2010-05-20
Director/Board Member 72 2012-09-27
Director/Board Member 55 2019-03-25
Date Insider Type Main position Quantity % Market Cap. Importance
9/30/26 Free

Director

6,351 0.0010%
6/30/26 Free

Director

6,103 0.0010%
5/20/26 Free

Director

220,000 0.0343%
Change 5-day change 1-year change 3-year change Capi.($)
-0.88%-4.27%-9.68%-38.80% 720M
+2.41%+0.29%+39.41%+72.14% 64.69B
-0.15%+7.50%+11.42%+71.27% 54.78B
+0.57%+4.60%+7.71%+90.93% 53.49B
+0.37%+4.67%+26.68%+49.64% 45.98B
-1.21%+2.32%+21.50%+118.33% 42.94B
-0.37%+5.07%+243.23%+789.58% 40.08B
+0.05%+0.21%+18.06%+48.50% 33.52B
+1.19%-4.98%+26.31%-0.76% 23.97B
-0.38%+5.68%+38.39%+28.35% 23.67B
Average +0.16%+1.74%+42.30%+122.92% 38.38B
Weighted average by Cap. +0.39%+2.72%+45.91%+142.50%

Financials

2026 *2027 *
Net sales 235M 210M 194M 176M 329M 22.34B 335M 2.34B 925M 11.71B 883M 864M 36.91B 341M 305M 281M 255M 477M 32.37B 485M 3.39B 1.34B 16.96B 1.28B 1.25B 53.48B
Net income -28.18M -25.17M -23.25M -21.07M -39.42M -2.68B -40.07M -280M -111M -1.4B -106M -104M -4.42B 49.18M 43.92M 40.57M 36.77M 68.79M 4.67B 69.93M 488M 193M 2.45B 185M 181M 7.71B
Net Debt - -
Projected Income Statement - Annual - Geron Corporation
Logo Geron Corporation
Geron Corporation is a commercial-stage biopharmaceutical company. The Company develops first-in-class telomerase inhibitor, RYTELO (imetelstat) for the treatment of adult patients with low- to intermediate-1 risk myelodysplastic syndromes (lower-risk MDS), with transfusion-dependent (TD) anemia requiring four or more red blood cell units over eight weeks who have not responded to or have lost response to or are ineligible for erythropoiesis-stimulating agents (ESAs). RYTELO is supported by the high unmet need in lower-risk MDS, including the observed benefit of RYTELO in difficult-to-treat subpopulations, such as patients with high transfusion burden and ring sideroblast negative (RS-) patients. It is also engaged in conducting a pivotal Phase III clinical trial of imetelstat in JAK-inhibitor relapsed/refractory myelofibrosis (R/R MF), as well as studies in other myeloid hematologic malignancies.
Employees
258
Date Price Change Volume
26-10-23 $1.120 -0.88% 11,233,211
26-10-22 $1.130 -2.59% 7,178,600
26-10-21 $1.160 -6.45% 8,915,716
26-10-20 $1.240 +3.33% 3,564,971
26-10-19 $1.200 +2.56% 4,909,640
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BB
MarketScreener Ratings - Geron Corporation
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
1.120USD
Average target price
4.250USD
Spread / Average Target
+279.46%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Geron Corporation
  1. Stock Market
  2. Stocks
  3. GERN Stock